A pre-workout injection that sends IGF-1 surging during the training window sounds like a direct line to better muscle performance. Two peptide combinations dominate that conversation: tesamorelin with GHRP-6, and CJC-1295 without DAC paired with the same ghrelin mimetic. Both aim to exploit the natural pulsatility of growth hormone release, but their timing, duration, and downstream effects differ sharply. Understanding those differences matters for anyone mapping a protocol around the workout clock.
How Tesamorelin and CJC-1295 No DAC Drive Different GH Profiles
Tesamorelin is a synthetic 44-amino-acid peptide analogue of growth hormone-releasing hormone. It binds the GHRH receptor with high affinity and triggers a discrete, rapid GH pulse. In a 2010 study by Falutz and colleagues in AIDS, a single subcutaneous dose produced a GH peak within 90 minutes and returned to baseline by roughly four hours. That short, sharp profile makes it a candidate for precise pre-workout timing.
CJC-1295 without DAC, also called Mod GRF 1-29, is a truncated 29-amino-acid GHRH analogue. It lacks the drug affinity complex that extends half-life, so its GH pulse is similarly brief. Research by Jetté and co-authors in a 2005 Endocrinology paper showed that the no-DAC variant clears rapidly, with GH returning to baseline within two to three hours. The key difference from tesamorelin is receptor affinity and a slightly faster offset, which can influence the shape of the IGF-1 response.
When either is combined with GHRP-6, a growth hormone secretagogue receptor agonist, the GH pulse amplitude multiplies. GHRP-6 independently stimulates GH release and blunts somatostatin tone. The result is a synergistic spike that can push serum GH several-fold higher than either agent alone. That spike is what athletes chase for pre-workout IGF-1 elevation.
IGF-1 Kinetics and the Pre-Workout Window
IGF-1 does not rise instantly after a GH pulse. Liver-derived IGF-1 takes hours to appear in circulation, but local IGF-1 splice variants in muscle may increase faster. A 2017 paper by Kraemer and colleagues in Sports Medicine noted that intramuscular IGF-1 mRNA can upregulate within 60 to 120 minutes of a GH surge. For a pre-workout protocol, that means the GH spike must precede the training session by enough time to initiate local IGF-1 signalling.
Tesamorelin with GHRP-6, injected 45 to 60 minutes before training, places the GH peak squarely in the early phase of exercise. Blood flow to working muscle rises, potentially enhancing peptide distribution. The IGF-1 response then builds through the session and into the post-workout period when nutrient uptake is highest. This is a 2 of 3 on evidence quality, based on pharmacokinetic modelling rather than direct muscle biopsy data in athletes.
CJC-1295 no DAC with GHRP-6 follows a similar timeline but with a slightly earlier GH peak, often around 30 to 45 minutes post-injection. Some users report a more pronounced initial rush, though objective data are sparse. The shorter GH tail may mean the IGF-1 signal decays sooner, which could matter for longer training sessions. A 2019 review by Veldhuis and Bowers in Endocrine Reviews emphasised that GH pulse duration is a critical determinant of IGF-1 transcriptional activation.
Cost and Practical Constraints of Each Combination
Tesamorelin is a prescription peptide with a higher price point. Vials typically cost $48 to $65 each when sourced through compounding pharmacies, and a daily protocol can run around $200 a month. GHRP-6 adds roughly $30 to $50 per month. The total monthly outlay often exceeds $250, which prices out casual experimentation.
CJC-1295 no DAC is widely available as a research chemical. A 5 mg vial commonly sells for $25 to $40, and GHRP-6 sits in a similar range. A monthly protocol using 100 mcg of each per injection might cost $80 to $120. That affordability makes it the default entry point, but purity and fill weights vary between vendors. Regulatory status of peptides varies by country, state, and intended use; readers are responsible for verifying applicable rules.
Storage and reconstitution add another layer. Tesamorelin often comes in a premixed pen or single-dose vial, reducing handling errors. CJC-1295 no DAC and GHRP-6 require bacteriostatic water, sterile vials, and careful refrigeration. A single mistake in reconstitution can degrade the peptide or introduce contaminants.
Comparing Hexarelin and Other Adjuncts in the Pre-Workout Stack
Hexarelin is a potent GHRP with a stronger GH-releasing effect than GHRP-6, but it carries a higher risk of prolactin and cortisol elevation. In a 2002 study by Arvat and colleagues in Journal of Endocrinological Investigation, hexarelin raised cortisol by 40% above baseline at higher doses. That spike could blunt the anabolic environment if timed poorly. Some athletes swap GHRP-6 for hexarelin on heavy training days, but the trade-off requires careful monitoring.
BPC-157, a gastric pentadecapeptide, does not directly stimulate GH but may accelerate recovery when used alongside GHRH/GHRP combos. A 2018 paper by Gwyer and co-authors in Frontiers in Pharmacology documented faster tendon healing in rodent models, though human data remain thin. Adding BPC-157 to a pre-workout injection complicates timing because its effects are local and prolonged, not acute. Most protocols separate it by several hours from GH peptides.
MK-677, an oral ghrelin mimetic, produces a sustained GH elevation over 24 hours rather than a sharp pulse. That profile is poorly suited to a pre-workout spike strategy. A 2018 study by Sigalos and Pastuszak in Translational Andrology and Urology noted that MK-677 raises IGF-1 by roughly 40% over weeks, not minutes. Using it alongside a pre-workout peptide stack creates overlapping GH signals that may desensitise receptors over time.
Timing Protocols to Maximise Muscle Performance
The tesamorelin plus GHRP-6 protocol hinges on a 45-to-60-minute pre-workout window. Inject subcutaneously, then begin training as the GH peak arrives. The session should last 45 to 75 minutes to capture the IGF-1 upswing. Eating immediately after training provides substrate for the IGF-1-driven anabolic phase. This approach aligns with the peptide's four-hour GH tail, avoiding a crash mid-session.
CJC-1295 no DAC with GHRP-6 works best with a 30-to-45-minute lead time. The faster GH peak suits shorter, high-intensity sessions. Some athletes split the dose, taking half before and half during training, but that practice lacks published safety data. The shorter GH duration means post-workout nutrition timing becomes even more critical to sustain the anabolic signal.
Both protocols demand an empty stomach for optimal GHRP-6 activity. Food, especially fat, blunts ghrelin receptor signalling. A 2013 paper by Müller and colleagues in Molecular Metabolism confirmed that even small amounts of dietary fat reduce GH response to ghrelin agonists by 30% or more. Fasting for two to three hours before injection is standard advice.
Evidence Quality and Gaps in the Literature
The evidence for pre-workout IGF-1 spiking as a performance enhancer is indirect. Most data come from GH deficiency studies, not athletic populations. The tesamorelin literature, including the 2010 Falutz paper, focused on visceral fat reduction in HIV patients, not muscle performance. Extrapolating those findings to healthy athletes is a 2 of 5 on evidence quality.
CJC-1295 no DAC has even less human data. Most pharmacokinetic work derives from animal models or small phase I trials. The synergy with GHRP-6 is well-characterised in endocrinology research, but the translation to gym performance relies on mechanistic reasoning rather than controlled trials. Self-administration of unapproved compounds carries risks that are not fully characterised in the published literature.
A 2021 review by Anderson and colleagues in Growth Hormone & IGF Research called for studies examining pulsatile GH delivery and muscle protein synthesis in trained individuals. Until those exist, protocols remain speculative. The 2-of-3 rating for tesamorelin timing reflects consistent pharmacokinetic data but absent performance outcomes.
Putting the Pieces Together Without Overreaching
Tesamorelin offers a longer, cleaner GH pulse that fits a standard training hour. CJC-1295 no DAC provides a cheaper, faster spike that may suit abbreviated sessions. Both rely on GHRP-6 to amplify the signal, and both demand precise fasting and injection timing. The choice often comes down to cost, with tesamorelin running around $200 monthly and the CJC-1295 combo under $100.
Adding hexarelin or BPC-157 changes the risk profile and the timing calculus. Hexarelin's cortisol bump can undercut the anabolic intent if dosed too close to training. BPC-157 belongs in a recovery slot, not a pre-workout syringe. MK-677, with its 24-hour GH elevation, works against the pulsatile strategy entirely.
The pre-workout IGF-1 spike remains an appealing concept with a thin evidence base. Athletes who choose to experiment should track objective metrics like session performance and recovery markers, not just subjective feel. The peptides discussed here are not approved for performance enhancement, and their long-term safety in healthy adults is unknown. If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.